EHA Congress 2026: key results and trends

With 17.3-mo median follow-up, Tec significantly improved PFS vs PVd/Kd (HR, 0.29; 95% CI, 0.23–0.38; P<0.0001); mPFS: NR vs 8.2 mo; 18-mo PFS rate: 69.8% vs 26.9%.

Anselamimab-treated patients with κ iFLC had a 62% reduction in ACM (HR = 0.38; 95% CI, 0.17, 0.86; nominal P = 0.012) and a 71% reduction in risk for CVH (estimated CVH rate ratio = 0.29; 95% CI, 0.10, 0.87; nominal P = 0.028).

A statistically significant improvement in PFS was demonstrated with epcor vs CIT (HR, 0.74 [95% CI, 0.60–0.92]; P=0.0059; 24-mo PFS: 30% vs 13%).

A significantly greater proportion of patients in the MY008211A arm achieved the primary endpoint compared with the eculizumab arm (50.0% versus 9.1%; odds ratio, 19.0; 95% CI, 3.62–99.67; P=0.0005 for superiority).

Median overall survival (OS) was NE in both arms (HR: 0.94, 95% CI: 0.33–2.67).

At 2 years, PFS, EFS and OS were 19% (12-26), 17% (10-23) and 39% (30-47) vs. 18% (11-24), 17% (10-23) and 42% (33-50).

With a median observation time of 24.6 months, there was no statistically significant difference between Pola-R-ICE and R-ICE at 2 years in EFS (26% vs 30%), PFS (47% vs 41%) and OS (75% vs 64%).

The observed PFS benefit of Mosun-Pola over R-GemOx was similar in 2L (HR, 0.38; 95% CI: 0.22–0.67) and 3L+ (HR, 0.48; 95% CI: 0.29–0.81) subgroups.

First line EPAG treatment significantly improved trilineage ORR after 12 wks (48.8% [95 % CI, 34.3; 63.5] vs. 25% ([95 % CI, 14.4; 39.6] p=0.02) and 24 wks (71.4% [95 % CI, 54.8; 83.8],in 35/41 pts) vs. 42.5% [95 % CI, 28.5; 57.8]; in 40/44pts; p = 0.011).

Median investigator-assessed PFS was not estimable (NE; 95% CI 74.81–NE) for DVRd and was 50.20 mo (95% CI 41.95–62.95) for VRd (hazard ratio [HR] 0.55; 95% CI 0.39–0.78; P=0.0007), with 59.3% for DVRd vs 38.3% for VRd alive and progression free at 72 mo.

At 24 months, estimated PFS was 76.9% (95% CI 66.4%–84.4%) in the Early P1101 group versus 43.1% (95% CI 30.6%–55.0%) in the Delayed P1101 group.

In the intention-to-treat (ITT) population, median OS in the BVd arm was not reached (NR; 95% CI, 63.0 months-NR) and was 58.3 months (95% CI, 41.4 months-NR) in the DVd arm (HR, 0.62; 95% CI, 0.46-0.82).